Header

News Archive

The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.

Showing 50 results

March 2024

Media ReleaseMar 21, 2024
Novartis Canada’s statement on CADTH draft recommendations for LEQVIO® (inclisiran)
Montréal, QC, March 21, 2024 – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is deeply disappointed with the draft recommendations of the Canadian Drug Expert Committee (CDEC) issued by…

December 2023

Media ReleaseDec 05, 2023
Mark Vineis appointed as the new Country President of Novartis Canada
Montreal, Quebec, December 5, 2023 — Novartis Canada announces that Mark Vineis has been appointed to the role of Country President, effective as of January 1, 2024. Mark brings a wealth of…

May 2023

Media ReleaseMay 18, 2023
Novartis Canada launches new head office in the Health Innovation District of Montréal, featuring a unique environment to inspire co-creation, partnerships and continued healthcare innovation
Novartis has a long-standing history in Canada, and is committed to delivering improved outcomes for millions of patients. In 2022, Novartis invested a total of $450 million in Canada.The office has…

February 2023

Media ReleaseFeb 10, 2023
Novartis partners with network of secondary prevention clinics to redefine the standard of care for cardiovascular disease prevention and treatment in Ontario
Novartis has begun collaborating with seven clinics across the province to support the prevention, identification and management of atherosclerotic cardiovascular disease (ASCVD) In Ontario,…

September 2022

August 2022

Media ReleaseAug 31, 2022
Scemblix™, a first-in-class CML treatment with new mechanism of action approved in Canada
Scemblix provides a new option for chronic myeloid leukemia (CML) patients who have had two or more previous tyrosine kinase inhibitor (TKI) treatments1 New mechanism of action with Scemblix…

June 2022

April 2022

Media ReleaseApr 25, 2022
Ontario and Quebec become the first provinces to list Kesimpta® (ofatumumab) for the treatment of adults with relapsing remitting multiple sclerosis (RRMS)
Kesimpta® is the first and only B-cell therapy for RRMS that can be administered by patients in the safety and convenience of their home Kesimpta® delivers superior efficacy with a favourable…

December 2021

Media ReleaseDec 17, 2021
Beovu® (brolucizumab injection) now publicly reimbursed in Ontario and New Brunswick for the treatment of neovascular (wet) age-related macular degeneration
Beovu® is an anti-VEGF that offers the option for eligible patients to start on a three-month dosing interval immediately after the loading phase with no compromise in efficacy. 1,2 While wet age-…

October 2021

Media ReleaseOct 27, 2021
Novartis launches Not Another Minute to educate Canadians and take action to bend the curve of cardiovascular disease (CVD)
In Canada, cardiovascular disease accounted for more than 52,000 deaths annually between 2015 and 20191 Almost 80% of deaths from cardiovascular disease are preventable2. Novartis is joining…